NCT03286101已完成2 期
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial On The Efficacy And Safety Of Topical 0.5% Ivermectin Lotion For The Treatment Of Head Lice Infestation Among Filipino Children Age 3 Years Or Older
United Laboratories1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2017年9月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment.
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of a single application of 0.5% ivermectin lotion in Filipino subjects with head lice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Index subjects must have an active lice infestation defined as: At least 3 live lice (adult and/or nymphs) present on the scalp and/or hair as determined by a trained evaluator; After the index subject has been enrolled, additional infested household members will be enrolled.
- •Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and /or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self- assess, as being lice free).
- •Subject is male or female;
- •Subject is at least 3 years old or older at the time of enrollment;
- •Subject is in good general health based on the medical history;
- •Each adult subject must have an appropriately signed Informed Consent agreement. For children, parents/guardian must sign an Informed Parental Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form
- •The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in the study. No more than one working male per household maybe excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility, otherwise the entire household will be excluded from study participation.
- •Subject and/or caregiver must be physically able and willing to report to the testing center for the supervised application of the product.
- •Subjects agrees not to use any other form of lice treatment (commercial or mechanical/manual) while participating in the study;
- •Following application and rinsing of the test product, subject agrees not to shampoo / wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed;
- •Subject agrees to not cut or chemically treat their hair while participating in the study;
- •Subject agrees to follow all study instructions.
排除标准
- •History of irritation or sensitivity to ivermectin or lotion components pediculosis or hair care products;
- •Presence of visible skin / scalp conditions that are not attributable to head lice infestation, such as erythema, blisters, vesicles which in the opinion of the investigative personnel will interfere with safety and / or efficacy evaluations;
- •Subjects suffering from psoriasis, atopic dermatitis or other conditions, which in the opinion of the investigator may compromise the objective of the study;
- •Treatment for head lice (OTC, home remedy or Rx) in the last 14 days;
- •Subjects under treatment which in the opinion of the investigator will interfere with the study results;
- •Subjects who participated in a previous investigational drug study within the past 30 days;
- •Subjects who does not understand the requirements for the study participation and/ or likely exhibit poor compliance, in the opinion of the investigator;
- •Females who are pregnant or lactating.
- •Living in a household where at least one member is pregnant, lactating, or planning a pregnancy
- •Subjects with skin lesions, specifically skin breaks are excluded because of possible absorption of the drug
研究组 & 干预措施
0.5% Ivermectin Lotion
Experimental
干预措施: 0.5% Ivermectin lotion (Drug)
Vehicle control
Placebo Comparator
干预措施: Vehicle (Drug)
结局指标
主要结局
Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment.
时间窗: Day 2 to day 15 after product application
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study With SAGE-547 for Super-Refractory Status EpilepticusSuper-Refractory Status EpilepticusNCT02477618Supernus Pharmaceuticals, Inc.132
进行中（未招募）
3 期
Clinical Study of Divozilimab in Patients With Systemic SclerodermaSystemic SclerodermaNCT05726630Biocad152
Unknown
4 期
Smoking Cessation Program in the Preadmission ClinicSmokingNCT00937508University Health Network, Toronto290
已完成
3 期
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's DiseaseCrohn's DiseaseNCT01277666GlaxoSmithKline608
已完成
2 期
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusType1 Diabetes MellitusNCT03117998REMD Biotherapeutics, Inc.154